{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:31:00Z","timestamp":1790706660456,"version":"4.1.0"},"reference-count":48,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["VU 2014-6703"],"award-info":[{"award-number":["VU 2014-6703"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,9,20]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Health-related quality of life (HRQoL) is impaired in paediatric patients with acute lymphoblastic leukaemia (ALL). Over the past decades, ALL treatment has successfully been adjusted to the risk of relapse, which is now reflected by the stratification of patients into three risk groups who receive treatment of differing intensities. This study is the first to evaluate the longitudinal course of HRQoL in light of these adjustments and identify determinants of HRQoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Two prospective, national cohort studies (add-on studies within the two most recent treatment protocols for children with ALL (ALL-10 and ALL-11)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Dutch paediatric oncology hospitals between October 2006 and October 2009 (ALL-10) and between August 2013 and July 2017 (ALL-11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with ALL (2\u201318 years) are treated according to the ALL-10 or ALL-11 treatment protocol. Patients treated according to the ALL-10 protocol only completed a cancer-specific QoL measure and patients treated according to the ALL-11 protocol completed both a cancer-specific and generic QoL measure (see below).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>HRQoL, assessed with parent-proxy questionnaires (PedsQL Generic and Cancer module) within the first 5 months (T0), at 1 year (T1), 2 years (T2) and 3 years (T3) after diagnosis. The proportion of patients with clinically relevant generic HRQoL impairment was compared with healthy norm values. Multivariable mixed model analyses were used to evaluate the development of HRQoL over time and its medical and sociodemographic determinants (collected on enrolment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the ALL-10 cohort, 132 families participated and of the ALL-11 cohort, 136 families participated (268 total). Thus, cancer-specific HRQoL assessments were available for 268 patients (median age 5.3 years (IQR 6.15), 56.0% boys, 69.0% medium-risk ALL), and generic HRQoL assessments for 136 patients (median age 4.8 years (IQR 6.13), 60.3% boys, 75.0% medium-risk ALL). Generic HRQoL improved between timepoints T0 and T3 (total score B 16.1, 95% CI 12.2 to 20.1, p&lt;0.001), but did not restore to normal 1 year after the end of treatment: 28.0% of children remained impaired compared with 16% in the general population (p=0.003). Cancer-specific HRQoL generally improved from T0 to T2 (Pain B 11.3, 95% CI 7.1 to 15.5; Nausea B 11.7, 8.4 to 15.1; Procedural Anxiety B 19.1, 14.8 to 23.4; Treatment Anxiety B 12.8, 9.5 to 16.0; Worry B 3.5, 0.6 to 6.3; Communication B 8.5, 5.0 to 11.9; all p&lt;0.001 except for Worry (p=0.02)), while Physical Appearance and Cognitive Functioning remained stable. Higher treatment intensity and experiencing pain or simultaneous chronic illness were associated with lower HRQoL over time for multiple subscales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HRQoL impairment is prevalent during and after ALL treatment. Patients with standard-risk ALL and reduced treatment intensity have better HRQoL than patients in higher risk groups. Systematic monitoring of HRQoL is of utmost importance in order to provide timely psychosocial interventions and supportive care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070804","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T21:35:54Z","timestamp":1698615354000},"page":"e070804","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Health-related quality of life and its determinants during and after treatment for paediatric acute lymphoblastic leukaemia: a national, prospective, longitudinal study in the Netherlands"],"prefix":"10.1136","volume":"13","author":[{"given":"Emily R","family":"Schwartz","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1683-6331","authenticated-orcid":false,"given":"Niki","family":"Rensen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"},{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M H","family":"Steur","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinoud","family":"Gemke","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K A","family":"van Eijkelenburg","sequence":"additional","affiliation":[{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M","family":"van der Sluis","sequence":"additional","affiliation":[{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pediatric Oncology, Erasmus MC Sophia Children Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja","family":"Dors","sequence":"additional","affiliation":[{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pediatric Oncology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van den Bos","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"},{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J E","family":"Tissing","sequence":"additional","affiliation":[{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pediatric Oncology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha A","family":"Grootenhuis","sequence":"additional","affiliation":[{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan J L","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"},{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele R L","family":"Van Litsenburg","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Emma Childrens\u2019 Hospital UMC, Amsterdam, The Netherlands"},{"name":"Department of Hematology-oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,29]]},"reference":[{"key":"2025121404331085000_13.10.e070804.1","unstructured":"DutchChildhoodOncologyGroup . SKION Jaarverslag. 2018. Available: https:\/\/www.skion.nl\/workspace\/uploads\/Skion-Jaarverslag-2018_1.pdf"},{"key":"2025121404331085000_13.10.e070804.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"2025121404331085000_13.10.e070804.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"2025121404331085000_13.10.e070804.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1547-5069.2005.00058.x"},{"key":"2025121404331085000_13.10.e070804.5","doi-asserted-by":"crossref","unstructured":"Fardell JE , Vetsch J , Trahair T , et al . Health-related quality of life of children on treatment for acute lymphoblastic leukemia: a systematic review. Pediatr Blood Cancer 2017;64. doi:10.1002\/pbc.26489","DOI":"10.1002\/pbc.26489"},{"key":"2025121404331085000_13.10.e070804.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25433"},{"key":"2025121404331085000_13.10.e070804.7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cncr.31085","article-title":"Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: a report from the children\u2019s oncology group AALL0932 trial","volume":"124","author":"Zheng","year":"2018","journal-title":"Cancer"},{"key":"2025121404331085000_13.10.e070804.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2349-2"},{"key":"2025121404331085000_13.10.e070804.9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/scs.12739","article-title":"Quality of life in children with acute lymphoblastic leukaemia","volume":"34","author":"Jankowska-Pola\u0144ska","year":"2020","journal-title":"Scand J Caring Sci"},{"key":"2025121404331085000_13.10.e070804.10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ijc.29708","article-title":"Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: results of children\u2019s oncology group study AALL0331","volume":"138","author":"Mitchell","year":"2016","journal-title":"Int J Cancer"},{"key":"2025121404331085000_13.10.e070804.11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pbc.26615","article-title":"Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: a cohort study","volume":"64","author":"Eiser","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2025121404331085000_13.10.e070804.12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s11136-018-1788-5","article-title":"Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review","volume":"27","author":"Vetsch","year":"2018","journal-title":"Qual Life Res"},{"key":"2025121404331085000_13.10.e070804.13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/pon.6060","article-title":"Quality of life of long-term childhood acute lymphoblastic leukemia survivors: comparison with healthy controls","volume":"31","author":"Chantziara","year":"2022","journal-title":"Psychooncology"},{"key":"2025121404331085000_13.10.e070804.14","first-page":"3897","article-title":"The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia","volume":"24","author":"Daniel","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025121404331085000_13.10.e070804.15","article-title":"Pain, sleep patterns and health-related quality of life in paediatric patients with cancer","volume":"28","author":"Nunes","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2025121404331085000_13.10.e070804.16","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-200401000-00001"},{"key":"2025121404331085000_13.10.e070804.17","doi-asserted-by":"publisher","DOI":"10.3109\/2000-1967-020"},{"key":"2025121404331085000_13.10.e070804.18","unstructured":"DutchChildhoodOncologyGroup . Protocol ALL 10 version 1.4. 2011. Available: https:\/\/www.skion.nl\/workspace\/uploads\/20110207Protocol-DCOG-ALL-10_with-amendments.pdf"},{"key":"2025121404331085000_13.10.e070804.19","unstructured":"DutchChildhoodOncologyGroup . Protocol ALL-11 version 9.0. 2018. Available: https:\/\/www.skion.nl\/workspace\/uploads\/C1--ALL11-Protocol-v9-0_03-09-2018.pdf"},{"key":"2025121404331085000_13.10.e070804.20","unstructured":"DutchChildhoodOncologyGroup . Protocol ALL-11 version 10.0: treatment study protocol of the dutch childhood oncology group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia utrecht; 2020."},{"key":"2025121404331085000_13.10.e070804.21","first-page":"4503","article-title":"Predicting trajectories of behavioral adjustment in children diagnosed with acute lymphoblastic leukemia","volume":"24","author":"Sint Nicolaas","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025121404331085000_13.10.e070804.22","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28165","article-title":"High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy","volume":"67","author":"Steur","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2025121404331085000_13.10.e070804.23","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz320","article-title":"Sleep-wake rhythm disruption is associated with cancer-related fatigue in pediatric acute lymphoblastic leukemia","volume":"43","author":"Steur","year":"2020","journal-title":"Sleep"},{"key":"2025121404331085000_13.10.e070804.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112779","article-title":"Parental sleep, distress, and quality of life in childhood acute lymphoblastic leukemia: a longitudinal report from diagnosis up to three years later","volume":"14","author":"Rensen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025121404331085000_13.10.e070804.25","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200108000-00006"},{"key":"2025121404331085000_13.10.e070804.26","unstructured":"Varni JW . Scaling and scoring the Pedsql. 2017. Available: https:\/\/www.pedsql.org\/PedsQL-Scoring.pdf"},{"key":"2025121404331085000_13.10.e070804.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10428"},{"key":"2025121404331085000_13.10.e070804.28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11136-019-02365-9","article-title":"Determinants of health-related quality of life proxy rating disagreement between caregivers of children with cancer","volume":"29","author":"Rensen","year":"2020","journal-title":"Qual Life Res"},{"key":"2025121404331085000_13.10.e070804.29","unstructured":"CentraalBureauStatistiek . Standaard onderwijsindeling 2016 den Haag\/Heerlen. 2016. Available: https:\/\/www.cbs.nl\/nl-nl\/onze-diensten\/methoden\/classificaties\/onderwijs-en-beroepen\/standaard-onderwijsindeling--soi--\/standaard-onderwijsindeling-2016"},{"key":"2025121404331085000_13.10.e070804.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.06.007"},{"key":"2025121404331085000_13.10.e070804.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-020-02387-0","article-title":"The reliability of the health related quality of life questionnaire PedsQL 3.0 cancer module in a sample of Swedish children","volume":"20","author":"Sand","year":"2020","journal-title":"BMC Pediatr"},{"key":"2025121404331085000_13.10.e070804.32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/jayao.2017.0089","article-title":"Self-perceived physical attractiveness in relation to scars among adolescent and young adult cancer survivors: a population-based study","volume":"7","author":"Olsson","year":"2018","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2025121404331085000_13.10.e070804.33","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200202000-00010"},{"key":"2025121404331085000_13.10.e070804.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3205"},{"key":"2025121404331085000_13.10.e070804.35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/pon.4186","article-title":"Intellectual development of childhood ALL patients: a multicenter longitudinal study","volume":"26","author":"Sleurs","year":"2017","journal-title":"Psychooncology"},{"key":"2025121404331085000_13.10.e070804.36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jpepsy\/jsaa086","article-title":"Longitudinal trajectories of neurocognitive functioning in childhood acute lymphoblastic leukemia","volume":"46","author":"Partanen","year":"2021","journal-title":"J Pediatr Psychol"},{"key":"2025121404331085000_13.10.e070804.37","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1216366"},{"key":"2025121404331085000_13.10.e070804.38","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-6-103","article-title":"Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study","volume":"6","author":"de Vries","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"2025121404331085000_13.10.e070804.39","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22725"},{"key":"2025121404331085000_13.10.e070804.40","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27728","article-title":"Gender-specific differences in parental health-related quality of life in childhood cancer","volume":"66","author":"Rensen","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2025121404331085000_13.10.e070804.41","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-006-0068-y"},{"key":"2025121404331085000_13.10.e070804.42","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsn007"},{"key":"2025121404331085000_13.10.e070804.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0651-1"},{"key":"2025121404331085000_13.10.e070804.44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11136-011-9962-z","article-title":"Why perform a quality or quality-of-life assessment","volume":"21","author":"Barofsky","year":"2012","journal-title":"Qual Life Res"},{"key":"2025121404331085000_13.10.e070804.45","first-page":"S426","article-title":"Psychosocial assessment as a standard of care in pediatric cancer","volume":"62 Suppl 5","author":"Kazak","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2025121404331085000_13.10.e070804.46","doi-asserted-by":"publisher","DOI":"10.1037\/cpp0000043"},{"key":"2025121404331085000_13.10.e070804.47","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24096"},{"key":"2025121404331085000_13.10.e070804.48","first-page":"550","article-title":"The impact of educating parents of leukemic children on the patients' quality of life","volume":"13","author":"Hashemi","year":"2011","journal-title":"Iran Red Crescent Med J"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:33:21Z","timestamp":1765715601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,29]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjopen-2022-070804"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070804","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}